Substantial doubt about the company's ability to continue as a going concern.
“The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to increase revenues, generate cash from operations, and/or generate cash from financing activities.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
BioLargo said Clyra Medical’s ViaCLYR was used on hundreds of patients following March 2026 launch, with evaluation at a system operating almost 20 hospitals and 200 clinics. Distribution reaches approximately 85% of the U.S. market and 18 Middle East countries.
BioLargo's proxy statement seeks stockholder approval at its December 1, 2026 annual meeting to elect seven directors, advisory-approve executive compensation, and ratify Hacker Johnson & Smith PA as independent registered public accounting firm for fiscal year 2026.
